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Pseudomyxoma peritonei (PMP) is a rare, chronic
and poorly understood disease. It is characterized
by mucinous ascites and a protracted clinical
course with multiple recurrences despite surgery
and/or chemotherapy. There is limited data avail-
able addressing the reproductive prognosis in
these patients. Also, the course of pregnancy in
these patients is largely unknown. Only three preg-
nancies in patients with PMP have been reported
to date.1
Management of PMP during pregnancy is chal-
lenging, requiring a balance of concern for mater-
nal survival and fetal health and wellbeing. The
management plan, which may require induced
abortion, is determined by the stage of pregnancy
and the predicted behavior of the malignancy
grade. We present here the medical history of a pa-
tient having an ovarium mucinous tumor with
large volume pseudomyxoma peritonei syndrome
during pregnancy and the treatments that she had
at our institution. A review of the literature regard-
ing this clinical situation and a discussion of treat-
ment options are presented.
CASE REPORT
A 19 - year - old primigravida woman at 25 weeks
of gestation was complaining of difficulty to breath
due to progressive enlargement of abdominal cir-
cumference. She was reffered from Singaraja Hos-
pital for further management. She also had a his-
tory of laparotomy (unilateral salphingo-oophorec-
tomy) due to ovarian cystoma in 2007 and there
were no records available of the first surgery. No
enlargement of abdomen before the pregnancy.
She also complained to have difficulty in defeca-
tion.
On physical examination, the abdomen appeared
to be swollen and the flanks were full. There was
a firm, non-tender, mobile mass in almost the
whole abdominal area. Complete blood count,
blood sugar, urine analysis, and serum creatinine
level were all within normal level. Serum albumin
was 3.3 gm/dl. Protrombin time 12.8 sec (control
13.2 sec), AST 242.2 IU/l, ALT 159.40 IU/l, HbsAg
and anti HCV were negative, CA125 249.95 U/ml,
CA19-9 192.81 U/ml. Ultrasonogram of abdomen
revealed ovarian cystoma with loculated immobile
ascites and the pregnancy was within normal limit.
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Diagnostic aspiration of ascitic fluid revealed yel-
lowish thick gelatinous material. Cytology of this
material was no malignant cell.
We diagnosed this patient with primigravida
single live 25-26 weeks fetus with suspected
pseudomyxoma peritonei. We decided to wait until
the pregnancy reached full term and opted for a
cesarean section as the method for childbirth and
continued with cytoreductive surgery (CRS).
On April 6th 2011 (38 weeks of gestation), the
patient underwent a cesarean section and deliv-
ered a healthy baby boy, weighing 2900 gram. We
found yellowish, gelatinous material covered the
pelvic cavities (± 1000cc). The cytological finding
was confirmed as the same as that described ear-
lier. The left ovary was found to be replaced by a
regular and cystic tumor, measuring approximately
30x20x10cm and there was no sign of rupture cyst.
The cut surface of the resected tumor appeared
multilobular and mucin producing tumor was con-
firmed. We also found tumor at anterior right peri-
toneum. The counter part ovarium was no longer
exist (history of salphingooophorectomy in 2007).
The appendix, small and large bowel, liver and
stomach appeared normal. Great omentum was
suspicious and covered by mucin implants. Frozen
section revealed a borderline mucinous cystade-
noma of ova-rium and the washing were negative
for malignant cells.
A total abdominal histerectomy, left salphingo-
oophorectomy, appendisectomy, omentectomy and
partial peritonectomy was performed. We also use
dextrose 10% (3000cc) for peritoneal lavage. She
did not receive heated intraperitoneal chemother-
apy (HIPEC) as there were no facilities available.
The final pathology confirmed a mucinous border-
line ovarian tumor (intestinal type) with cytology
no malignant cell, hyperplasia mesothel of perito-
neum and omentum and early acute appendicitis.
Postoperative recovery was going well. In follow
up at one year after, the patients and her son are
in good condition, tumor marker, ultrasonography
and CT scan showed no abnormalities. She has got
hormonal replacement therapy due to menopause
praecox.
DISCUSSION
Pseudomyxoma peritonei (PMP) was first descri-
bed by Rokitansky in 1842. It is an uncommon con-
dition characterized by abundant extracellular
mucinous material in the peritoneal cavity and tu-
moural implants on the peritoneal and the epiploic
surfaces. Incidence is one per million per year and
encountered in 2 of 10,000 laparotomies with ge-
latinous masses called "jelly belly".1
PMP is three to four times more common in
women than in men. The median age of presenta-
tion is 54 years. PMP is commonly thought to arise
from either an appendiceal or an ovarian neo-
plasm. Both these organs are found to be involved
in the majority of female patients, thereby making
the primary site of origin controversial. Appen-
Figure 1. Fetus biometry at gestational age of 25 weeks
(left).
 
Figure 2. Gelatinous fluid was found at cavum abdomen
during surgery (arrow).
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diceal lesions reported in association with PMP in-
clude mucosal hyperplasia, benign cystadenoma
and cystadenocarcinoma. Ovarian lesions including
primary ovarian cystadenocarcinoma or mucinous
borderline tumours were previously thought to be
the site of origin. Several recent reports have sug-
gested that involvement of the ovaries is secondary
to a primary origin in the appendix. However if
there is no abnormalities in appendix, we have to
think that the source of PMP is from ovarian.1,2
Symptoms may include abdominal or pelvic pain
and or bloating, distension, digestive disorders,
weight changes, increase girth and infertility. The
disease is sometimes incidentally discovered dur-
ing surgery for other conditions. The diagnosis of
PMP is often difficult. It usually has an insidious
presentation. Ultrasonography is frequently per-
formed as the initial diagnostic procedure. Typical
findings are nonmobile echogenic ascites with mul-
tiple semisolid masses and scalloping of the hepatic
and splenic margin. Furthermore ultrasound may
be helpful in diagnostic and therapeutic paracen-
tesis, as mucin is difficult to aspirate. CT of the ab-
domen and pelvis is the most widely applied tech-
nology and has been used with great success in the
diagnosis of the PMP syndrome. CT scan findings
may be pathognomonic for PMP, include areas of
low attenuation, with island of higher attenuation
due to solid elements within mucinous material.
Classically scalloping of visceral surfaces, particu-
larly of the liver and spleen, distinguishes muci-
nous from fluid ascites. The diagnosis of PMP is
made clinically when gelatinous mucin is found fill-
ing the abdominal cavity. In our case, we did not
perform CT scan because the patient was preg-
nant.2,3
Sugarbaker advocated the measurement of CEA
levels but do not report any data on levels in their
patients. A few authors have retrospectively re-
ported the levels of CEA and CA19-9 in very small
numbers of patients. These anecdotal data indicate
only that levels of CEA and, perhaps CA19-9, are not
infrequently raised in patients with pseudomyxo-
ma peritonei and may rise in association with re-
current disease. In a report of four patients with
pseudomyxoma peritonei and mucinous ovarian
tumours, three also had a raised CA125 level. In our
case, the level of CA125 and CA19-9 were rising be-
fore surgery and went normal limit after the sur-
gery.4
The histogenesis of this entity remains unclear,
simple rupture of mucinous lesion is not sufficient
to explain the cause of PMP. In this case, PMP may
occur from the prior surgery of ovarian cystoma.
it might be a spillage of ovarian cystoma to the ca-
vum abdomen. PMP can theoretically be prevented
at the time of oophorectomy by ensuring that the
specimen is sent intact with no spillage of cells in-
traperitoneally and PMP may develop as long as 10
years from the initial tumor presentation. This syn-
drome is now more approximately classified as dis-
seminated peritoneal adenomucinousis (DPAM)
primary tumor adenoma, minimal to moderate
atypia and no significant mitoses, peritoneal muci-
nous carcinomatosis (PMCA) primary tumor carci-
noma, marked atypia, signet ring cells, or interme-
diate in nature.2
 In this case, there is a paucity of evidence to
guide the clinician in optimal management. Mater-
nal health and timely treatment of PMP is balanced
by health and safety of the fetus, as abdominal ex-
tensive surgery, is known could cause preterm la-
bor. Therefore during pregnancy, in addition to
prognosis of PMP, the stage and value of the preg-
nancy must also be considered. Koops and col-
leagues recommend that definitive treatment of
PMP could be delayed to allow pregnancy to occur
if the disease was minimally aggressive. In patients
with progressive disease, their experience with de-
lay led to an advanced, untreatable disease state.
Based on previous case reports, it appears reason-
able to carry out a diagnostic surgical evaluation of
PMP during pregnancy, ideally in the second or
third trimester. If a patient presents with an acute
abdomen from a ruptured mucinous tumor, initial
Figure 3. Mucinous tumor (left ovary). Pathology re-
ported as borderline.
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surgery should consist of a complete appendec-
tomy and mesoappendectomy, and biopsy of
omental or peritoneal tumor deposits. Since the
rate of lymph node positivity in mucinous neo-
plasms is less than 5%, more extensive surgery at
the time of initial diagnosis is not warranted and
poses undue risk to the mother and fetus.4
Definitive management of moderate or low gra-
de ovarian cancer with pseudomyxoma peritonei
should be delayed until after delivery, as extensive
cytoreduction and intraperitoneal chemotherapy
would be impossible and contraindicated during
pregnancy. It is reasonable to have the delivery at
an earlier date, 34-35 weeks gestation, in order not
to further delay treatment of cancer. The method
for childbirth is important if the delivery is to occur
prior to definitive cytoreduction. A vaginal delivery
is required. A Cesarean section is contraindicated.
An abdominal incision for Cesarean section will al-
low for mucinous cancer cells to implant and pro-
gress within the abdominal incision and parame-
trial tissues. This would potentially compromise
the completeness of cytoreduction and the likeli-
hood of a curative result. If a Caesarian section is
necessary for obstetrical reasons, a midline inci-
sion should be used, which can be excised with
subsequent cytoreductive surgery.4
Due to difficulty of breath and defecation are re-
leaved with massive paracentesis, the cytology was
no malignant cells, also considering the patients
and her husband were attempting this pregnancy,
we decided to postponed the definitive surgery un-
til the pregnancy is term. We decided to do ce-
sarean section to this patients due to the head of
baby was not engaged until term and we continue
to do definitive treatment after that. We did radical
surgery in this patient because there was no point
to leave uterus alone without ovarium. Appendis-
ectomy was performed to find the primary source
of this syndrome. Omentectomy and peritonecto-
my were performed to find any metastase and to
improve the prognosis. Dextrose solution and
other agents have been suggested for peritoneal
lavage. This solution can loosening mucinous de-
posits. PMP has generally been considered benign,
however its behaviour suggests that it should, at
least, be considered a borderline malignancy with
disease progression over time, to massive abdomi-
nal distension and nutritional compromise in most
cases. There has recently been a global interest in
the management of PMP, particularly in macro-
scopic removal by complex surgical techniques
combined with HIPEC. In this case, we did not com-
bine the surgery with HIPEC due to there were no
facilities available. Most studies report very little
improvement in disease free or overall survival
with systemic chemotherapy. We decided not to
give systemic chemotherapy because according to
literature, it is not give any advantages to PMP.4-6
CONCLUSION
In patients with slow or moderate advance of dis-
ease, the pregnancy (or pregnancy wish) should be
allowed to proceed until term. In patients with a
rapid progression, termination of the pregnancy
and definitive treatment may be necessary to pro-
tect the mother.
REFERENCES
1. Sait KH. Pseudomyxoma peritonei: diagnosis and manage-
ment. Med Sci 2006; 13(1): 21-32.
2. Mukherjee A, Moran BJ. Pseudomyxoma peritonei: symp-
toms, signs and clinical differential diagnosis. CME J Gynecol
Oncol 2003; 8: 199-203.
Table 1. Suggested Management Strategy for Pseudomyxoma Peritonei Syndrome Occurring during Pregnancy.4
Gestational age
(weeks)
Aggressive malignancy Low-moderate malignancy
Diagnostic test CRS and HIPEC Diagnostic test CRS and HIPEC
 0 — 12 Not safe Consider
pregnancy
termination
Not safe Delay treatment
to
35 weeks












164  Aditanzil et al Obstet Gynecol
3. Niwa K, Morishita S, Murase T, Kawabata I, Imai A, Shimo-
kawa K. Successful pregnancy in a patient with pseudo-
myxoma peritonei arising from ovarian mucinous cystade-
nocarcinoma treated with cisplatin. Gynecol Oncol 1995;
59: 398-400.
4. Haase E, Yoo D, Sugarbaker PH. Management of appendiceal
pseudomyxoma peritonei diagnosed during pregnancy.
World J Sur Oncol 2009; 7: 48-53.
5. Djordjevic B, Stojanovic S, Ljubenovic N, Djordjevic I. Pseu-
domyxoma peritonei and mucinous ovarian tumors. Acta
Med Medianae 2008; 48(1): 46-9.
6. Jarvinen P, Lepisto A. Clinical presentation of pseudomy-
xoma peritonei. Scandinavian J Sur 2010; 99: 213-6
|
Vol 1, No 3
July 2013 Pseudomyxoma peritonei syndrome during pregnancy  165
